Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
New Disease-Modifying Therapies and New Challenges for MS.
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
The olfactory vector hypothesis of neurodegenerative disease: is it viable?
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis.
Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
[Cognitive impairment in demyelinating disease].
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.
The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial.
SMAD family proteins: the current knowledge on their expression and potential role in neoplastic diseases.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO.
Laquinimod Halted MS Disability But Not Relapses
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.
Building a better sphingosine kinase-1 inhibitor.
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Pages
« first
‹ previous
…
167
168
169
170
171
172
173
174
175
…
next ›
last »